Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

α-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2.

Wang S, Xu B, Liou LC, Ren Q, Huang S, Luo Y, Zhang Z, Witt SN.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16119-24. doi: 10.1073/pnas.1206286109. Epub 2012 Sep 17.

2.

Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo.

Oueslati A, Schneider BL, Aebischer P, Lashuel HA.

Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):E3945-54. doi: 10.1073/pnas.1309991110. Epub 2013 Aug 27.

3.

In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.

Bergeron M, Motter R, Tanaka P, Fauss D, Babcock M, Chiou SS, Nelson S, San Pablo F, Anderson JP.

Neuroscience. 2014 Jan 3;256:72-82. doi: 10.1016/j.neuroscience.2013.09.061. Epub 2013 Oct 12.

PMID:
24128992
4.

Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.

Qing H, Wong W, McGeer EG, McGeer PL.

Biochem Biophys Res Commun. 2009 Sep 11;387(1):149-52. doi: 10.1016/j.bbrc.2009.06.142. Epub 2009 Jul 1.

PMID:
19576176
5.

PLK2 modulates α-synuclein aggregation in yeast and mammalian cells.

Basso E, Antas P, Marijanovic Z, Gonçalves S, Tenreiro S, Outeiro TF.

Mol Neurobiol. 2013 Dec;48(3):854-62. doi: 10.1007/s12035-013-8473-z. Epub 2013 May 17.

PMID:
23677647
6.

LK6/Mnk2a is a new kinase of alpha synuclein phosphorylation mediating neurodegeneration.

Zhang S, Xie J, Xia Y, Yu S, Gu Z, Feng R, Luo G, Wang D, Wang K, Jiang M, Cheng X, Huang H, Zhang W, Wen T.

Sci Rep. 2015 Jul 29;5:12564. doi: 10.1038/srep12564.

7.

Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein.

Rodríguez-Nogales C, Garbayo E, Martínez-Valbuena I, Sebastián V, Luquin MR, Blanco-Prieto MJ.

Int J Pharm. 2016 Nov 30;514(1):142-149. doi: 10.1016/j.ijpharm.2016.06.044.

PMID:
27863657
8.

Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.

Schildknecht S, Gerding HR, Karreman C, Drescher M, Lashuel HA, Outeiro TF, Di Monte DA, Leist M.

J Neurochem. 2013 May;125(4):491-511. doi: 10.1111/jnc.12226. Epub 2013 Mar 19. Review.

10.

DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.

Zondler L, Miller-Fleming L, Repici M, Gonçalves S, Tenreiro S, Rosado-Ramos R, Betzer C, Straatman KR, Jensen PH, Giorgini F, Outeiro TF.

Cell Death Dis. 2014 Jul 24;5:e1350. doi: 10.1038/cddis.2014.307.

11.

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H.

Neuron. 2009 Dec 24;64(6):807-27. doi: 10.1016/j.neuron.2009.11.006.

12.

Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.

PMID:
23743292
13.

The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro.

Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, Paunovic V, Ardah MT, El-Agnaf OM, Kostic V, Markovic I, Trajkovic V.

Neurobiol Dis. 2014 Mar;63:1-11. doi: 10.1016/j.nbd.2013.11.002. Epub 2013 Nov 20.

PMID:
24269733
14.

Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.

Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bezard E, Vila M.

Ann Neurol. 2014 Mar;75(3):351-62. doi: 10.1002/ana.24066. Epub 2014 Feb 18.

PMID:
24243558
15.

Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system.

Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schöbel S, Frigon NL, Yu M, Caccavello RJ, Nelson S, Motter R, Wright S, Chian D, Santiago P, Soriano F, Ramos C, Powell K, Goldstein JM, Babcock M, Yednock T, Bard F, Basi GS, Sham H, Chilcote TJ, McConlogue L, Griswold-Prenner I, Anderson JP.

J Biol Chem. 2009 Jan 30;284(5):2598-602. doi: 10.1074/jbc.C800206200. Epub 2008 Nov 12.

16.

Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Yang XW.

J Neurosci. 2009 Feb 18;29(7):1962-76. doi: 10.1523/JNEUROSCI.5351-08.2009.

17.

Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.

Alerte TN, Akinfolarin AA, Friedrich EE, Mader SA, Hong CS, Perez RG.

Neurosci Lett. 2008 Apr 11;435(1):24-9. doi: 10.1016/j.neulet.2008.02.014. Epub 2008 Feb 12.

18.

The pathogenesis of cell death in Parkinson's disease--2007.

Olanow CW.

Mov Disord. 2007 Sep;22 Suppl 17:S335-42. doi: 10.1002/mds.21675. Review.

PMID:
18175394
19.

α-Synuclein is a pathological link and therapeutic target for Parkinson's disease and traumatic brain injury.

Shahaduzzaman M, Acosta S, Bickford PC, Borlongan CV.

Med Hypotheses. 2013 Oct;81(4):675-80. doi: 10.1016/j.mehy.2013.07.025. Epub 2013 Aug 6.

PMID:
23920272
20.

Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.

Buck K, Landeck N, Ulusoy A, Majbour NK, El-Agnaf OM, Kirik D.

Neurobiol Dis. 2015 Jun;78:100-14. doi: 10.1016/j.nbd.2015.03.008. Epub 2015 Mar 25.

PMID:
25818009

Supplemental Content

Support Center